Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6
Open Access
- 1 January 2003
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in The Pharmacogenomics Journal
- Vol. 3 (2), 105-113
- https://doi.org/10.1038/sj.tpj.6500160
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Antipsychotic Drugs: Prolonged QTc Interval, Torsade de Pointes, and Sudden DeathAmerican Journal of Psychiatry, 2001
- Plasma concentrations of haloperidol are related toCYP2D6genotype at low, but not high doses of haloperidol in Korean schizophrenic patientsBritish Journal of Clinical Pharmacology, 2001
- SCHIZOPHRENIAMedical Clinics of North America, 2001
- The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: A preliminary study in a psychiatric populationPsychiatry and Clinical Neurosciences, 1999
- Isolation of a novel potassium channel gene hSKCa3 containing a polymorphic CAG repeat: a candidate for schizophrenia and bipolar disorder?Molecular Psychiatry, 1998
- Excess mortality of schizophreniaThe British Journal of Psychiatry, 1997
- Characterization of the cytochrome P450 isoenzymes involved in the in vitro N -dealkylation of haloperidolBritish Journal of Clinical Pharmacology, 1997
- The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytesBritish Journal of Pharmacology, 1997
- Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: implications for the involvement of cytochrome P450IID6European Journal of Clinical Pharmacology, 1993
- Haloperidol Disposition Is Dependent on Debrisoquine Hydroxylation PhenotypeTherapeutic Drug Monitoring, 1992